argenx to Present at TD Cowen 45th Annual Healthcare Conference
argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled for Monday, March 3, 2025 at 11:50 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will remain available on the company website for approximately 30 days following the presentation.
argenx is listed on both Euronext and Nasdaq under the ticker symbol ARGX.
argenx, un'azienda globale di immunologia focalizzata sul miglioramento della vita delle persone con gravi malattie autoimmuni, ha annunciato che Tim Van Hauwermeiren, Amministratore Delegato, presenterà alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La presentazione è programmata per lunedì 3 marzo 2025 alle 11:50 a.m. ET.
Investitori e parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Investitori del sito web di argenx su argenx.com/investors. Una registrazione del webcast rimarrà disponibile sul sito dell'azienda per circa 30 giorni dopo la presentazione.
argenx è quotata sia su Euronext che su Nasdaq con il simbolo ticker ARGX.
argenx, una empresa global de inmunología centrada en mejorar la vida de las personas con enfermedades autoinmunes graves, ha anunciado que Tim Van Hauwermeiren, Director Ejecutivo, presentará en la 45ª Conferencia Anual de Salud de TD Cowen. La presentación está programada para lunes 3 de marzo de 2025 a las 11:50 a.m. ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de Inversores del sito web de argenx en argenx.com/investors. Una repetición del webcast estará disponible en el sitio web de la empresa durante aproximadamente 30 días después de la presentación.
argenx está cotizada en Euronext y Nasdaq bajo el símbolo de ticker ARGX.
argenx는 심각한 자가면역 질환을 앓고 있는 사람들의 삶을 개선하는 데 집중하는 글로벌 면역학 회사로, Tim Van Hauwermeiren CEO가 TD Cowen 제45회 연례 의료 회의에서 발표할 것이라고 발표했습니다. 발표는 2025년 3월 3일 월요일 오전 11시 50분 ET로 예정되어 있습니다.
투자자와 이해관계자는 argenx.com/investors의 argenx 웹사이트 투자자 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 웹캐스트의 재생은 발표 후 약 30일 동안 회사 웹사이트에서 제공될 것입니다.
argenx는 Euronext와 Nasdaq에 ARGX라는 티커 기호로 상장되어 있습니다.
argenx, une entreprise mondiale d'immunologie axée sur l'amélioration de la vie des personnes atteintes de maladies auto-immunes sévères, a annoncé que Tim Van Hauwermeiren, Directeur Général, présentera lors de la 45e Conférence Annuelle sur la Santé de TD Cowen. La présentation est prévue pour lundi 3 mars 2025 à 11h50 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseurs du site web d'argenx à argenx.com/investors. Un enregistrement du webinaire sera disponible sur le site de l'entreprise pendant environ 30 jours après la présentation.
argenx est cotée à la fois sur Euronext et Nasdaq sous le symbole boursier ARGX.
argenx, ein globales Unternehmen für Immunologie, das sich darauf konzentriert, das Leben von Menschen mit schweren Autoimmunerkrankungen zu verbessern, hat angekündigt, dass Tim Van Hauwermeiren, Geschäftsführer, auf der 45. jährlichen Gesundheitskonferenz von TD Cowen präsentieren wird. Die Präsentation ist für Montag, den 3. März 2025 um 11:50 Uhr ET angesetzt.
Investoren und Interessierte können über den Investorenbereich der argenx-Website unter argenx.com/investors auf einen Live-Webcast der Präsentation zugreifen. Eine Wiederholung des Webcasts wird für etwa 30 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
argenx ist sowohl an der Euronext als auch an der Nasdaq unter dem Tickersymbol ARGX gelistet.
- None.
- None.
February 25, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
When is Tim Van Hauwermeiren presenting at the TD Cowen Healthcare Conference for ARGX?
How can investors access argenx's (ARGX) presentation at the TD Cowen conference?
How long will the replay of ARGX's TD Cowen conference presentation be available?
What exchanges is argenx (ARGX) listed on?
What is argenx's (ARGX) primary business focus?
